CTOs on the Move


 
Our name, Aptuit, is derived from the words aptitude and intuition, two natural attributes that define our unique approach to providing drug discovery, development and manufacturing support. The name communicates our aptitude for scientific knowledge as well as our intuitive understanding of the needs of the pharmaceutical and biotechnological community. We summon these attributes to clarify current challenges and anticipate those that are to come, always with the determination to find solutions.   Since Aptuit was founded in 2004, we have forged a robust expansion of our resources. We are living up to the promise of our name by the ongoing assembly ...
  • Number of Employees: 10K-50K
  • Annual Revenue: $500M-1 Billion
  • www.aptuit.com
  • 2 Greenwich Office Park
    Greenwich, CT USA 06831
  • Phone: 855.506.6360

Executives

Name Title Contact Details

Similar Companies

Degraft-Johnson and Associates

Degraft-Johnson and Associates is a Chadds Ford, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Confluent Medical Technologies

Confluent Medical Technologies is the leading contract manufacturer of Nitinol-based components, balloon components, and balloon catheters.

Signant Health

We help you connect patients and researchers to ensure data reliability, with proven solutions that simplify every step of the patient journey. Our deep therapeutic area expertise, agile technology and service scale enable us to minimize risk, innovate, and support your important work. We seek speed, efficiency and reduced variability to help you extend the reach of drug development, expand patient opportunities and improve data quality helping you bring life-changing therapies to our families and communities around the world.

Nanotherapeutics

Nanotherapeutics is a Alachua, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Concert Pharmaceuticals

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company`s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting autoimmune and inflammatory diseases and central nervous systems (CNS) disorders.